Published January 12, 2018
Cancer biomarkers are used to trace and indicate the biological state of a tumour and thus analyse diagnostic and prognostic stages of cancer. Cancer biomarkers are into various fields such as drug discovery, development, personalised medicine, and diagnostics. Diagnostics is the principal revenue-generating application of market relating to factors such as increasing growth of biomarker-based oncology tests with higher sensitivity.
North America Cancer Biomarkers Market Segments Size & growth:
The market is valued at USD 3.996 Billion in 2017 and is expected to reach USD 7.328 Billion by 2024 at a CAGR of 10.11%. The major Key factors influencing the market growth are an increase in awareness among patients and healthcare professionals about the necessity of early diagnostics of malignance’s and rising demand for personalised medicine is anticipated to provide the market with significant growth.
North America Cancer Biomarkers Market Segments Share:
Cancer type segments cancer biomarkers market into breast cancer, lung cancer, colorectal cancer, melanoma; prostate, thyroid etc. over all these breast cancers is holding the most significant share in the market due to the prevalence of breast cancer and awareness about the diagnosis. The cancer biomarkers market is segmented by type, disease, service, application, and technologies. Of the kind, the market is categorised into protein biomarkers, genetic biomarkers, cell biomarkers, viral biomarkers, carbohydrate biomarkers. By disease, the market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer and cervical cancer. By service, the market is categorised into sample preparation, assay development, biomarkers validation and testing. By application, the market is classified into risk assessment, development of molecular diagnostics, disease diagnostics, drug discovery, and development. By technologies, the market is categorised into Omics technologies, imaging technologies, cytogenetics, bioinformatics and IVD multivariate index assays. Geographically, North America is the dominant region globally, and the United States is the primary contributor. Asia-Pacific is expected to be the fastest growing regional market due to the prevalence of cancer in that region.
North America Cancer Biomarkers Market Trends:
North America Cancer Biomarkers Market Research Report Includes:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The principal market players are:
1.1. Executive Summary
1.2. Market Definition
1.3. The scope of the Study
2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Analytics Tools & Model
2.4. Economic Indicators
2.4.1.Base Year, Base Currency & Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
3. Market Analysis
3.1. Industry Value Chain Analysis
3.2. Porter’s Five Force Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of Substitutes
3.2.4 Threat of New Entrants
3.2.5 Industry Rivalry (Competitive Environment)
3.3. PESTLE Analysis
3.4. SWOT Analysis
3.4.5 Y-O-Y Analysis
4. Market Dynamics
4.1.1 Increase in corporate partnerships to accelerate development and commercialise of regenerative medicine.
4.1.2 Increase in global healthcare expenditure.
4.1.3 Rapid growth in ageing population.
4.1.4. Prevalence of chronic diseases and genetic disorders.
4.2.1 Cost of treatment.
4.2.2 Complex regeneration process.
4.2.3. Lack of guidelines.
4.2.4. Ethical concerns with the use of embryonic stem cell for research and development.
4.3.1. Strong product pipeline.
4.3.2. The great demand for organ transplantation.
4.4.1 Stringent regulatory policies about stem cell technologies.
5. North America Cancer Biomarkers Market – By Disease
5.2 Prostate cancer
5.3 Lung cancer
5.4 Cervical cancer
5.5 Colorectal cancer
5.6 Breast cancer
6. North America Cancer Biomarkers Market – By Application
6.2 Risk assessment
6.3 Disease diagnostics
6.4 Development of molecular diagnostics
6.5 Drug formation
7. North America Cancer Biomarkers Market – By Service
7.2 Sample preparation
7.3 Assay development
7.4 Biomarkers validation and testing
8. North America Cancer Biomarkers Market – By Type
8.2 Protein biomarkers
8.3 Cell biomarkers
8.4 Genetic biomarkers
8.5 Carbohydrate biomarkers
8.6 Viral biomarkers
9. North America Cancer Biomarkers Market – By Technology
9.2 Omics technology
9.4 Imaging technologies
9.5 Immuno Assays
9.7 IVD multivariate
9.8 Index assays
10. North America Cancer Biomarkers Market – By Country
10.1 North America
10.1.2 United States
11. North America Cancer Biomarkers Market – Company Profiles
11.1 Affymetrix Inc
11.2 Agendia BV
11.3 Abbott Laboratories
11.4 Roche Diagnostics Corp.
11.5 Agilent Technologies
11.6 Astex Pharmaceuticals
11.7 Illumina Inc
11.8 Diadexus Inc
11.9 Qiagen N.V
11.10 Aureon Biosciences Inc
11.11 Becton, Dickinson and Company
11.12 Beckman Coulter Inc
11.13 Clarient Inc
11.14 Astellas Pharma US Inc
12. North America Cancer Biomarkers Market – Competitive Landscape
12.1 Market Share Analysis
12.2 Strategies Adopted by top companies
12.3 Merges, Acquisitions, Collaborations & Agreements
13. Market Insights
13.1 Industry Experts Insights
13.2 Analysts Opinions
13.3 Investment Opportunities
14.1 List of tables
14.2 List of figures